HilleVax Q1 2024 Earnings Report

Reported financial results for the first quarter of 2024 and highlighted recent company progress.

Key Takeaways

HilleVax reported a net loss of $46.8 million for the first quarter of 2024, with $272.7 million in cash, cash equivalents and marketable securities as of March 31, 2024. Topline data from the NEST-IN1 Phase 2B clinical study of HIL-214 in infants is expected in mid-2024.

Cash, cash equivalents and marketable securities totaled $272.7 million as of March 31, 2024.

Research and development expenses for the first quarter 2024 were $26.0 million.

General and administrative expenses for the first quarter 2024 were $8.5 million.

Net loss for the first quarter 2024 was $46.8 million.

Previous year: -$0.71

+36.6%

Research and Development Expenses

$26M